WHO ICTRP trial
A B2-agonist as a CFTR activator in CF - Part 2
NL-OMON43663 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON43663 |
|---|---|
| Public title | A B2-agonist as a CFTR activator in CF - Part 2 |
| Scientific title | A B2-agonist as a CFTR activator in CF - Part 2 - ABBA 2 |
| Primary sponsor | Universitair Medisch Centrum Utrecht |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | Cystic Fibrosis Mucoviscidosis;10083624;Cystic Fibrosis;Mucoviscidosis |
| Interventions | After baseline measurements all patients will be assigned to receive oral Salbutamol, during 8 weeks up untill 24 hours prior to the second study visit. ;CFTR activation;CFTR residual function;personalized medicine;Salbutamol |
| Registration date | Jan 29, 2016 |
| Target size | 20 |
| Secondary IDs | 2015-001317-28;NL53059.041.15 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: